Literature DB >> 26564004

Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions.

Thaer Khoury1, Prasanna R Kumar2, Zaibo Li3, Rouzan G Karabakhtsian4, Souzan Sanati5, Xiwei Chen6, Dan Wang6, Song Liu6, Beatriu Reig7.   

Abstract

There are certain criteria to recommend surgical excision for lobular neoplasia diagnosed in mammographically detected core biopsy. The aims of this study are to explore the rate of upgrade of lobular neoplasia detected in magnetic resonance imaging (MRI)-guided biopsy and to investigate the clinicopathological and radiological features that could predict upgrade. We reviewed 1655 MRI-guided core biopsies yielding 63 (4%) cases of lobular neoplasia. Key clinical features were recorded. MRI findings including mass vs non-mass enhancement and the reason for biopsy were also recorded. An upgrade was defined as the presence of invasive carcinoma or ductal carcinoma in situ in subsequent surgical excision. The overall rate of lobular neoplasia in MRI-guided core biopsy ranged from 2 to 7%, with an average of 4%. A total of 15 (24%) cases had an upgrade, including 5 cases of invasive carcinoma and 10 cases of ductal carcinoma in situ. Pure lobular neoplasia was identified in 34 cases, 11 (32%) of which had upgrade. In this group, an ipsilateral concurrent or past history of breast cancer was found to be associated with a higher risk of upgrade (6/11, 55%) than contralateral breast cancer (1 of 12, 8%; P=0.03). To our knowledge, this is the largest series of lobular neoplasia diagnosed in MRI-guided core biopsy. The incidence of lobular neoplasia is relatively low. Lobular neoplasia detected in MRI-guided biopsy carries a high risk for upgrade warranting surgical excision. However, more cases from different types of institutions are needed to verify our results.

Entities:  

Mesh:

Year:  2015        PMID: 26564004      PMCID: PMC5491967          DOI: 10.1038/modpathol.2015.128

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  In-situ lobular neoplasia: time for an awakening.

Authors:  Sunil R Lakhani
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

2.  Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years.

Authors:  P P Rosen; C Kosloff; P H Lieberman; F Adair; D W Braun
Journal:  Am J Surg Pathol       Date:  1978-09       Impact factor: 6.394

3.  Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates.

Authors:  Nehmat Houssami; Stefano Ciatto; Ian Ellis; Daniela Ambrogetti
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

4.  MR imaging-guided 9-gauge vacuum-assisted core-needle breast biopsy: initial experience.

Authors:  Susan G Orel; Mark Rosen; Carolyn Mies; Mitchell D Schnall
Journal:  Radiology       Date:  2005-11-22       Impact factor: 11.105

5.  Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment.

Authors:  P P Rosen; R Senie; D Schottenfeld; R Ashikari
Journal:  Ann Surg       Date:  1979-03       Impact factor: 12.969

Review 6.  Evolving concepts in the management of lobular neoplasia.

Authors:  Benjamin O Anderson; Kristine E Calhoun; Eric L Rosen
Journal:  J Natl Compr Canc Netw       Date:  2006-05       Impact factor: 11.908

7.  The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: a study of 100 cases from four academic institutions.

Authors:  Thaer Khoury; Zaibo Li; Souzan Sanati; Mohamed M Desouki; Xiwei Chen; Dan Wang; Song Liu; Rouzan Karabakhtsian; Prasanna Kumar; Beatriu Reig
Journal:  Histopathology       Date:  2015-10-05       Impact factor: 5.087

8.  Core biopsy of the breast with atypical ductal hyperplasia: a probabilistic approach to reporting.

Authors:  K A Ely; B A Carter; R A Jensen; J F Simpson; D L Page
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

9.  Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.

Authors:  David L Page; Peggy A Schuyler; William D Dupont; Roy A Jensen; W Dale Plummer; Jean F Simpson
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

10.  Lobular carcinoma in situ of the breast: clinical, radiological, and pathological correlation.

Authors:  Marion Scoggins; Savitri Krishnamurthy; Lumarie Santiago; Wei Yang
Journal:  Acad Radiol       Date:  2013-04       Impact factor: 3.173

View more
  5 in total

Review 1.  Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Authors:  Kelly L Mooney; Lawrence W Bassett; Sophia K Apple
Journal:  Mod Pathol       Date:  2016-08-19       Impact factor: 7.842

Review 2.  The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.

Authors:  Edi Brogi
Journal:  Virchows Arch       Date:  2022-05-14       Impact factor: 4.064

3.  Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma.

Authors:  Isabelle L Crary; Elizabeth U Parker; Kathryn P Lowry; Pranav P Patwardhan; Thing Rinda Soong; Sara H Javid; Kristine E Calhoun; Meghan R Flanagan
Journal:  Ann Surg Oncol       Date:  2022-07-08       Impact factor: 4.339

4.  High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy.

Authors:  Eumee Cha; Emily B Ambinder; Eniola T Oluyemi; Lisa A Mullen; Babita Panigrahi; Joanna Rossi; Philip A Di Carlo; Kelly S Myers
Journal:  Breast Cancer Res Treat       Date:  2022-10-15       Impact factor: 4.624

5.  Post-Operative Complications and Nipple Necrosis Rates Between Conventional and Robotic Nipple-Sparing Mastectomy.

Authors:  Jeea Lee; Hyung Seok Park; Haemin Lee; Dong Won Lee; Seung Yong Song; Dae Hyun Lew; Jee Ye Kim; Seho Park; Seung Il Kim
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.